Alpelisib decreases nevocytes of congenital melanocytic nevi.

Alejandra Tomás-VelázquezJuan Carlos López-GutiérrezCarlos de AndreaMiguel Reyes-MúgicaClaudia M SalgadoPedro Redondo Bellón

Published in: Journal of the European Academy of Dermatology and Venereology : JEADV (2023)

This study provides first-time evidence that alpelisib induces nevocyte reduction in CMN from patient-derived explants, probably inducted by autophagy. Alpelisib is an approved drug with an adequate safety profile used in another mosaicism affecting PI3K (PROS). Further studies are needed to evaluate its efficacy in treating CMN and potentially, their complications, either with local or systemic administration, alone or in combination.

Keyphrases

cell death
oxidative stress
signaling pathway
endoplasmic reticulum stress
risk factors
adverse drug
drug administration
electronic health record